Modulating the Amyloidogenesis of α-Synuclein.

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alpha-synuclein (α-synuclein) is a neuronal protein implicated in Parkinson's disease pathogenesis.
• Misfolded, oligomeric forms of α-synuclein are cytotoxic and form amyloid fibrils, a hallmark of Parkinson's disease.
• The native function of α-synuclein remains largely unknown, despite its association with neurodegeneration.

Purpose of the Study:

• To review strategies for inhibiting α-synuclein amyloidogenesis.
• To explore methods for stabilizing the native state of α-synuclein or redirecting its aggregation pathway.
• To identify potential therapeutic agents for Parkinson's disease based on α-synuclein inhibition.

Main Methods:

• Literature review of studies investigating α-synuclein aggregation inhibitors.
• Analysis of small molecules (e.g., polyphenols), peptides, and proteins as potential therapeutic agents.
• Evaluation of strategies aimed at preventing the formation of toxic α-synuclein species.

Main Results:

• Various agents, including small molecules, peptides, and proteins, have demonstrated efficacy in inhibiting α-synuclein aggregation.
• These agents protect cells from the cytotoxicity associated with misfolded α-synuclein.
• Stabilizing the native state or promoting less toxic aggregates are key inhibition strategies.

Conclusions:

• Inhibiting α-synuclein amyloidogenesis is a viable therapeutic strategy for Parkinson's disease.
• Small molecules, peptides, and proteins show potential for developing new treatments.
• Further research into these strategies could lead to effective therapies for combating Parkinson's disease.